Sign in
Active, not recruitingNo phase

Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry

Key facts

Who runs it
University of California, San Francisco
Where
Alpharetta, Austin, Chicago, Dallas, Dover, Durham, Homewood, Irvine, Irving, San Antonio, San Diego, and San Francisco, United StatesSee the 12 sites
Trial code
Status
Active, not recruiting
People taking part
578 people enrolled
Started
May 2014
Ended
30 Jun 2026
Type of study
Observational, 2 groups
Treatments tested
  • Radiofrequency ablation of fibroids
  • Myomectomy of fibroids
Record updated
27 April 2026

Who can take part

Age
21 years and older
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Planning to undergo or have undergone* RF ablation (Acessa) or myomectomy (laparoscopic or abdominal) for treatment of uterine fibroids
  • Able to give informed consent
  • Speak English or Spanish; Women enrolled at contracted clinical sites must enroll prior to their RF ablation treatment

Who cannot take part

  • <21 years of age
  • Plan to undergo hysteroscopic myomectomy

Where in United States

  • Fibroid and Pelvic Wellness Center of GeorgiaAlpharetta, United States
  • Tassone Advanced GynecologyAustin, United States
  • Gynecology Institute of ChicagoChicago, United States
  • UT SouthwesternDallas, United States
  • Dedicated to WomenDover, United States
  • Duke UniversityDurham, United States
  • Women's Healthcare Associates of IL, SCHomewood, United States
  • UC Irvine Medical CenterIrvine, United States
  • MacArthur Medical CenterIrving, United States
  • Acacia OBGYNSan Antonio, United States
  • University of California San DiegoSan Diego, United States
  • University of California San FranciscoSan Francisco, United States

About the trial

What the trial wants to find out

The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF ablation (Acessa).

Read full original descriptionShow less

The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone laparoscopic RF ablation (Acessa) or myomectomy within the United States. Participants will be recruited through study materials distributed at clinical offices across the country where gynecologists are performing laparoscopic RF ablation (Acessa). Study participants will consent to participate in a 3 year prospective study conducted by UCSF but the fibroid procedure will be performed by the study participants' own gynecologist. We will evaluate changes in fibroid-related symptoms from pre-treatment values to 6, 12, 18, 24, 30, and 36 months after RFA (Acessa). We will determine long-term efficacy of RFA (Acessa) by evaluating the rate of re-treatment for symptomatic fibroids after the RFA (Acessa) procedure versus myomectomy. Participants will be asked for permission to review their medical records to assess surgical and pregnancy outcomes.

UC San Francisco will have oversight of all scientific and administrative aspects of the study. All study data will be stored securely in a HIPAA compliant, secure database monitored by the UC San Francisco Coordinating Center.

The 2 groups in the trial

  • Women undergoing radiofrequency ablation.

    Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).

    Treatment: Radiofrequency ablation of fibroids

  • Women undergoing myomectomy

    About 25% of women in the trial will be in the group who receive treatment with myomectomy.

    Treatment: Myomectomy of fibroids

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
27 April 2026